Novo Nordisk completed the €10.66 billion acquisition of Catalent, including three production plants to scale up Wegovy production. Despite rivals' opposition, the deal secures Novo’s market...
Novo Nordisk's experimental weight-loss pill, amycretin, showed promising early-phase results, with patients losing up to 13.1% of their weight in 12 weeks. Side effects were mild...